Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer.
News items for the week of Nov. 18, 2019.
A large genome-wide association in breast cancer cases and controls from Japan led to common variants linked to disease risk at two new and nine known risk loci.
The technology, called PrecisMed, is designed to detect, measure, and assess over 200 medications in a patient's bloodstream from a finger stick.
Under the terms of the five-year grant, Coriell will continue to support the NINDS Human Genetics Research Center.
Functional enhancers can accompany oncogenes on the circularized extrachromosomal amplicons found in glioma and other tumors, enhancing cancer growth.
LGC provides customers across multiple markets with reference materials, proficiency testing, oligonucleotides, genomics reagents, and instrumentation.
The company's antibiotic-induced hearing loss test will be used to screen babies for a genetic mutation that can cause deafness when given certain antibiotics.
Doctors can now order the test to identify breast cancer patients with BRCA1/2 mutations who may be eligible for surgery or targeted therapy.
The grant was awarded through the Alzheimer's Drug Discovery Foundation's Diagnostic Accelerator, a partnership between the charity and philanthropic partners.
In a revised remedies proposal to the UK's Competition and Markets Authority, Illumina offered licenses to a wider swath of IP held by it and PacBio.
Using RNA sequencing, researchers profiled gene expression patterns in cutaneous leishmaniasis lesions, identifying a handful of genes with treatment-associated expression.
The Redwood, California-based company plans to use the funding to drive the commercial launch of its semiconductor chip-based sequencing-by-synthesis instrument.
The flow cytometry-based assays were developed by Menlo Park, California-based IncellDx to run on Beckman Coulter instrumentation.
The T2Resistance Panel, which runs on the T2Dx instrument, detects 13 genes conferring antimicrobial resistance directly from whole blood in three to five hours.
The company's revenues were generated entirely by its discovery services operations, which includes contract research for cancer drug development.
The funding will be used to adapt the company's web-based genomic data analysis methods platform for computational analyses developed for ENCODE.
The firm will use the net proceeds to repurchase up to about $50 million of its senior convertible note due 2034, as well as for general corporate purposes.
While higher recurrence scores have been associated with increased mortality in women, the pattern of the association differed among male patients.
The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.
The Ithaca, New York-based firm has submitted its molecular diagnostic instrument along with a test to detect chlamydia, gonorrhea, and trichomonas.
The amounts to be purchased of each of six separate classes of notes will be determined in accordance with the acceptance priority level determined by Roche.
The partners plan to employ Personalis' ImmunoID NeXT platform to investigate biomarkers of response and mechanisms of resistance to cancer therapies.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.